Biotech Values

[Mufaso]

Summary of Amylyn/DACRA NME's in development from piper posted on X:

Nice table for a quickie summary of the Amylin assets in development - also from Piper - .. $LLY $NVO $ABBV /Gubra $ROG / $ZEAL.CO $MTSR $VKTX $GPCR - Metsera mid-yr readout for their QM Amylin asset will be an important one - VKTX / GPCR still in IND enabling stage - so data in… pic.twitter.com/zOKTXks94W

— Sports_Bios (@Sports_bios) March 17, 2025

As for the difference between Amylin and DACRA's here is the response from Co-Pilot:

Dual Amylin and Calcitonin Receptor Agonists (DACRAs) and Amylin are related but distinct in their functions and applications:

DACRAs: These are a class of drugs that act as agonists at both the amylin receptor and the calcitonin receptor. They are being developed as therapies for conditions like obesity and type 2 diabetes. DACRAs combine the effects of amylin and calcitonin receptor activation, which can lead to improved glycemic control and weight loss.

Amylin: This is a naturally occurring peptide hormone co-secreted with insulin by the pancreas. It plays a role in regulating blood sugar levels by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety. Amylin analogs are used in diabetes management to mimic these effects